Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Ad5.F35-hGCC-PADRE |
Synonyms | |
Therapy Description |
Ad5.F35-hGCC-PADRE is a cancer vaccine comprising a recombinant type 5 adenovirus that encodes guanylyl cyclase C (GUCY2C) linked to a Pan DR Epitope (PADRE), which potentially enhances CD8-positive T-cell and antibody-mediated responses against GUCY2C-expressing tumor cells (Journal for ImmunoTherapy of Cancer 2015;3:P450). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Ad5.F35-hGCC-PADRE | Ad5-GUCY2C-PADRE | Ad5.F35-hGCC-PADRE is a cancer vaccine comprising a recombinant type 5 adenovirus that encodes guanylyl cyclase C (GUCY2C) linked to a Pan DR Epitope (PADRE), which potentially enhances CD8-positive T-cell and antibody-mediated responses against GUCY2C-expressing tumor cells (Journal for ImmunoTherapy of Cancer 2015;3:P450). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04111172 | Phase II | Ad5.F35-hGCC-PADRE | Phase 2A Study of Ad5.F35-hGCC-PADRE in Gastrointestinal Malignancies | Suspended | USA | 0 |